Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Down 80.5% in March

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 36,100 shares, a drop of 80.5% from the February 28th total of 184,900 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average trading volume of 99,800 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is owned by institutional investors.

Creative Medical Technology Stock Up 0.5 %

CELZ stock traded up $0.01 during mid-day trading on Wednesday, hitting $2.21. 278,987 shares of the company were exchanged, compared to its average volume of 41,285. The business has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $3.25. The firm has a market capitalization of $3.86 million, a P/E ratio of -0.58 and a beta of 1.70. Creative Medical Technology has a 12-month low of $1.91 and a 12-month high of $6.90.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.